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Abstract 
Background: To evaluate the utility of the Johns Hopkins Hospital Template in detection of 
high-grade urothelial carcinoma. Methods: A computerized search of our laboratory information 
system was performed for 2009 through 2011 for all urine cytology cases processed by the 
SurePath™. We included only cases with correlating surgical pathology within 6 months after 
the urinary samples were obtained. The original cytologic diagnoses were reclassified according 
to the Johns Hopkins Template and these cytologic diagnoses were then correlated with the 
followup surgical pathology diagnoses. Results: A total of 273 urine samples with 
histopathologic followup were identified. The reclassified cytologic diagnoses included negative 
for urothelial atypia or malignancy (NUAM) 110; atypical urothelial cells of undetermined 
significance (AUC-US) 83; atypical urothelial cells, cannot exclude high-grade urothelial 
carcinoma (AUC-H) 49; high-grade urothelial carcinoma (HGUC) 29; and low-grade urothelial 
carcinoma (LGUC) 2. More than one-half of patients (58%) who had biopsy-confirmed high-
grade urothelial lesions had a preceding cytologic diagnosis of AUC-H or HGUC. AUC-H and 
HGUC are associated with high-grade urothelial lesions in 80% and 90% of the cases and show 
statistical significance when compared with AUC-US or NUAM (P<0.05). Conclusion: The 
Hopkins Template is useful and effective in identifying patients with high-grade urothelial 
lesions who need to undergo cystoscopy.  
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Introduction 
 
Given its high sensitivity and specificity for the detection of high-grade urothelial tumors, 
urinary cytology continues to play an important role in the management of patients with 
urothelial carcinoma. Urinary cytology nicely compliments cystoscopic examination, a method 
that detects most low-grade urothelial tumors. Over the decades, several classification schemes 
for reporting urine cytology have been proposed and the nomenclature has evolved in accordance 
with changes in the histologic classification of the bladder cancers.1-5 However, unlike cervical 
cytology, there has not been widespread acceptance and use of any particular reporting scheme 
for urine cytology studies. The Johns Hopkins Hospital Template for Reporting Urine Cytology 
is the foundation for the newly proposed "Paris classification for reporting urine cytology" which 
has proposed 7 diagnostic categories for urine cytology samples, including negative for 
urothelial atypia or malignancy (NUAM); atypical urothelial cells of undetermined significance 
(AUC-US); atypical urothelial cells, cannot exclude high-grade urothelial carcinoma (AUC-H); 
high-grade urothelial carcinoma (HGUC); low-grade urothelial carcinoma (LGUC); other 
(squamous carcinoma, adenocarcinoma, etc.); and inadequate (Table 1).6,7 The aim of this study 
is to examine the applicability of this recently published diagnostic nomenclature. 
 
Material and Methods 
This study was approved by Indiana University Institutional Review Board (protocol number 
1401456334). A computerized search of our laboratory information system was performed for 
2009 through 2011 for all urine cytology cases processed by the SurePath (BD-TriPath Imaging, 
Burlington, NC) liquid-based preparation technique. Only cases with correlating surgical 
pathology samples (biopsies and/or resection specimens) obtained within 6 months after the 
urine cytology samples were included in the study. If there were multiple urine samples from the 
same patient before the biopsy, only the worst urine cytology diagnosis was included for 
analysis. In our institution, urinary cytology was reported using the descriptive term such as “no 
atypical cells identified,” “atypical urothelial cells,” “suspicious for urothelial carcinoma,” “low-
grade urothelial carcinoma,” “high-grade urothelial carcinoma,” etc. The original reports were 
transcribed into the Johns Hopkins Template. For example, “no atypical cells identified” cases 
were assigned to NUAM category, “atypical urothelial cells” were assigned to AUC-US 
category, and “suspicious for urothelial carcinoma” were assigned to “AUC-H.” The original 
cytologic slides were then re-reviewed by first author HHW and, based on the proposed 
cytologic criteria; they were reclassified according to the Hopkins Template.7 The urothelial cells 
demonstrating nuclear features of hyperchromasia, irregular nuclear membrane, high nucleus-to-
cytoplasm ratio, and anisonucleosis were classified as either AUC-H or HGUC depending on the 
quantity or quality of the cells. When the atypical cells did not show cytologic features of high-
grade urothelial carcinoma and were not consistent with normal or reactive urinary tract elements 
they were classified as AUC-US. These cytologic diagnoses were then correlated with the 
followup surgical pathology diagnoses. This study was blinded to the patients’ clinical history 
and outcome. 
Statistical Methods 
We used 2x2 tables to calculate sensitivity, specificity, positive predictive value, and negative 
predictive value. Fisher exact tests were used to evaluate statistical significance and two-tailed 
tests were used with P values ≤0.05 being considered statistically significant (IBM SPSS V.19.0, 
2010). 
 
Results 
A total of 273 urine samples with histopathologic followup were identified from 72 female and 
201 male patients ranging in age from 4 to 95 years with a mean age of 64. There were 220 
voided urine and 53 catheterized urine specimens. All urinary samples were prepared using the 
liquid-based SurePath method. After converting all of our original urine cytologic diagnoses into 
the Johns Hopkins Template nomenclature, we re-reviewed the SurePath slides of each case and 
reclassified the diagnoses into the appropriate category based on the proposed cytologic criteria. 
We upgraded NUAM to AUC-H in 4 cases and to AUC-US in 6 cases. In addition, 7 cases of 
AUC-US were upgraded to AUC-H. The majority of the original diagnoses remained unchanged. 
The final reclassified cytologic diagnoses included NUAM 110, AUC-US 83, AUC-H 49, 
HGUC 29, and LGUC 2. The followup histopathologic diagnoses for NUAM included benign 
nonneoplastic (BNN) 90, HGUC 15, LGUC 1, and nonurothelial cancers 4 (1 small cell 
carcinoma, 1 squamous carcinoma of cervical origin, 1 prostatic adenocarcinoma, and 1 
leiomyosarcoma). For AUS-US, surgical pathology followup included BNN 32, HGUC 33, 
LGUC 12, and nonurothelial cancers 6 (2 adenocarcinomas of the urinary bladder, 2 small cell 
carcinoma and 2 metastatic colonic adenocarcinomas). For AUC-H, the followup included BNN 
7, HGUC 39, LGUC 1, and nephrogenic adenoma 2. For LGUC, 2 cases diagnosed on urine 
cytology were confirmed by the followup surgical pathology. For HGUC, histopathologic 
followup included BNN 3 and HGUC 26. The rate of malignancy for NUAM, AUC-US, AUC-
H, and HGUC was 18%, 61%, 82%, and 90% respectively (Table 2). More than one-half of 
patients (58%) who had biopsy-confirmed HGUC had a preceding cytologic diagnosis of AUC-
H or HGUC. When patients with AUC-US were added to the analysis, 87% of patients with 
HGUC had at least one abnormal urinary cytology result. If we include AUC-US as abnormal 
results, the sensitivity, specificity, positive predictive value, and negative predictive value for 
detection of cancer is 86%, 67%, 73%, and 82% respectively (Table 3); but if we exclude AUC-
US and then the sensitivity, specificity, positive predictive value, and negative predictive value 
become 49%, 91%, 85%, and 63% (Table 4). Using a set of well-defined cytologic criteria for 
high-grade urothelial lesions such as hyperchromasia, irregular nuclear membrane, increased 
nucleus-to-cytoplasm ratio, and anisonucleosis, we found a high degree of association of AUC-H 
and HGUC with a histologic diagnosis of high grade urothelial carcinoma at 80% and 90%, 
respectively, versus 40% for AUC-US and 14% for NUAM (P<0.05).  
 
Discussion 
Urine cytology is a useful, inexpensive test for screening patients with hematuria or at risk for 
urothelial carcinoma. It has also been used for the surveillance of patients with urothelial 
carcinoma. The advantages of urine cytology include ease of obtaining the specimens and high 
sensitivity and specificity in diagnosing high-grade urothelial lesions.8 The most important 
indicator for the surgeons to have a patient undergo cystoscopy is a cytologic diagnosis of 
HGUC and the Johns Hopkins Hospital Template was designed for the purpose of targeting those 
patients who need cystoscopy.6 In our study, there was a high degree of association of AUC-H 
and HGUC with a histologic diagnosis of high-grade urothelial carcinoma at 80% and 90%. 
For 16 cases of low-grade urothelial lesions diagnosed by followup biopsies, only 2 of 16 
were correctly diagnosed as LGUC by urine cytology, while 12 were diagnosed as AUC-US, one 
as AUC-H, and one as NUAM . The cytologic features of LGUC include papillary-like clusters, 
irregular nuclear membrane, increased nucleus-to-cytoplasm ratio, and homogenous cytoplasm; 
however, these features are overlapping with reactive changes secondary to calculi, 
inflammation, and instrumentation that contribute to the difficulty in diagnosing LGUC by urine 
cytology.9 The two cases of LGUC diagnosed in our study relied on the cell block preparation in 
which well-defined papillary clusters with fibrovascular core were easily identified. 
In our study, none of the nonurothelial cancers including 2 adenocarcinomas of the 
urinary bladder, 3 small cell carcinoma, 2 metastatic colonic adenocarcinomas, 1 squamous 
carcinoma of cervical origin, 1 prostatic adenocarcinoma, and 1 leiomyosarcoma were diagnosed 
by urine cytology. The corresponding urinary cytologic diagnoses of these 10 cases were NUAM 
in 4 cases and AUC-US in 6 cases. All of the urine samples of these cases were voided urines. 
For cases with the presence of atypical cells in the urine cytology, the number of atypical cells 
was scant and they were not diagnostic of malignancy. 
The AUC-US diagnostic category encompasses a heterogenous group of lesions. In our 
study, 40% were HGUC, 39% were benign nonneoplastic and 21% showed LGUC or other 
nonurothelial cancers including adenocarcinoma of the urinary bladder, small cell carcinoma, 
and metastatic colonic adenocarcinoma. In contrast, the cytologic diagnoses of AUC-H and 
HGUC are highly associated with high-grade urothelial lesions in the urinary tract. None of the 
nonurothelial cancers and only one LGUC were diagnosed in the followup cases of AUC-H or 
HGUC. If we considered AUC-US as negative, the sensitivity, specificity, positive predictive 
rate, and negative predictive rate for detecting cancer would be 49%, 91%, 85%, and 93% versus 
86%, 67%, 73%, and 82%, respectively, if we included AUC-US as an abnormal result. The 
study by Brimo et al also showed a similar pattern of sensitivity and specificity of 46.3% and 
85%, respectively, if AUC-US was considered as negative and 82% and 45.4% if AUC-US was 
considered as an abnormal result.10  
The cytologic features of HGUC were well preserved with the liquid-based SurePath 
preparation.11 In our laboratory, the most important cytologic feature of high-grade urothelial 
lesions, hyperchromasia, was well visualized on the SurePath slides that also contributed to the 
high correlation of AUC-H and HGUC with high-grade urothelial lesions in the followup 
biopsies.  
The Johns Hopkins Template for Reporting Urinary Cytology was created for targeting 
patients with high-grade urothelial lesions who need to undergo cystoscopy. We have confirmed 
the effectiveness of using this template for the interpretation of urinary cytology samples that 
were prepared by the liquid-based SurePath method. In this study, the urine cytology diagnosis 
of AUC-H or HGUC is highly associated with a histologic diagnosis of high-grade urothelial 
lesions and shows statistical significance (P<0.05) when compared with the diagnosis of AUC-
US. We agree that the diagnosis of AUC-H and HGUC warrants a cystoscopic examination, but 
the diagnosis of AUC-US was also noted to have cancers in 61% of the followup biopsies that 
also requires close clinical correlation and followup. 
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Table 1 Diagnostic categories of the Johns Hopkins Template for urinary tract cytologic samples 
 
NUAM No urothelial atypia or malignancy identified 
AUC-US Atypical urothelial cells of uncertain significance 
AUC-H Atypical urothelial cells, cannot exclude HGUC 
HGUC High-grade urothelial carcinoma 
LGUC Low-grade urothelial carcinoma 
Other Squamous carcinoma, adenocarcinoma, etc. 
Inadequate Absence of urothelial cells or washing with low cellularity, etc 
 
 
 
  
Table 2 Followup histologic correlation of urinary cytology cases using the Hopkins Template 
 
Hopkins 
Template 
Followup 
Histology 
NUAM  
(n=110) 
AUC-US 
(n=83) 
AUC-H 
(n=49) 
HGUC 
(n=29) 
LGUC 
(n=2) 
Total 
(n= 273) 
BNN 
 
90 32 7 3  132 
HGUC 
 
15 33 39 26  113 
LGUC 
 
1 12 1  2 16 
Cancer – 
Others 
4 6    10 
Nephrogenic 
adenoma 
  2   2 
Malignancy 
Rate 
18% 61% 82% 90% 100% 51% 
HGUC Rate 
 
14% 40% 80% 90% 0% 41% 
BNN, Benign nonneoplastic; AUC-H, atypical urothelial cells, cannot exclude high-grade urothelial carcinoma; 
AUC-US, atypical urothelial cells of undetermined significance; HGUC, high-grade urothelial carcinoma; LGUC, 
low-grade urothelial carcinoma; NUAM, negative for urothelial atypia or malignancy 
 
 
Table 3 Urine cytology includes AUC-US as abnormal. 
 
Urine Cytology 
Followup Histology 
Negative  
(NUAM) (n=110) 
Positive  
(AUC-US + AUC-H + HGUC 
+ LGUC) (n=163) 
Malignant 20 119 
Benign 90 44 
Sensitivity 86% 
Specificity 67% 
Positive predictive value 73% 
Negative predictive value 82% 
AUC-H, atypical urothelial cells, cannot exclude high-grade urothelial carcinoma; AUC-US, atypical urothelial 
cells of undetermined significance; HGUC, high-grade urothelial carcinoma; LGUC, low-grade urothelial 
carcinoma; NUAM, negative for urothelial atypia or malignancy 
 
 
 
 
 
  
Table 4 Urine cytology includes AUC-US as negative. 
 
Urine Cytology 
Followup Histology 
Negative  
(NUAM + AUC-US) 
(n=193) 
Positive  
(AUC-H + HGUC +LGUC) 
(n=80) 
Malignant 71 68 
Benign 122 12 
Sensitivity 49% 
Specificity 91% 
Positive predictive value 85% 
Negative predictive value 63% 
AUC-H, atypical urothelial cells, cannot exclude high-grade urothelial carcinoma; AUC-US, atypical urothelial 
cells of undetermined significance; HGUC, high-grade urothelial carcinoma; LGUC, low-grade urothelial 
carcinoma; NUAM, negative for urothelial atypia or malignancy 
 
